TW201932487A - 單域抗體－胞嘧啶脫氨酶融合蛋白及其製備方法、藥物組合物、及其用途 - Google Patents

單域抗體－胞嘧啶脫氨酶融合蛋白及其製備方法、藥物組合物、及其用途 Download PDF

Info

Publication number
TW201932487A
TW201932487A TW108100438A TW108100438A TW201932487A TW 201932487 A TW201932487 A TW 201932487A TW 108100438 A TW108100438 A TW 108100438A TW 108100438 A TW108100438 A TW 108100438A TW 201932487 A TW201932487 A TW 201932487A
Authority
TW
Taiwan
Prior art keywords
seq
fusion protein
functional variant
domain antibody
group
Prior art date
Application number
TW108100438A
Other languages
English (en)
Chinese (zh)
Inventor
陳佩君
李叔樺
Original Assignee
順天醫藥生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 順天醫藥生技股份有限公司 filed Critical 順天醫藥生技股份有限公司
Publication of TW201932487A publication Critical patent/TW201932487A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW108100438A 2018-01-04 2019-01-04 單域抗體－胞嘧啶脫氨酶融合蛋白及其製備方法、藥物組合物、及其用途 TW201932487A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862613653P 2018-01-04 2018-01-04
US62/613,653 2018-01-04

Publications (1)

Publication Number Publication Date
TW201932487A true TW201932487A (zh) 2019-08-16

Family

ID=67058005

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108100438A TW201932487A (zh) 2018-01-04 2019-01-04 單域抗體－胞嘧啶脫氨酶融合蛋白及其製備方法、藥物組合物、及其用途

Country Status (14)

Country Link
US (2) US20190202931A1 (OSRAM)
EP (1) EP3735420A4 (OSRAM)
JP (2) JP2021511013A (OSRAM)
KR (1) KR20200106032A (OSRAM)
CN (1) CN112272673A (OSRAM)
AU (1) AU2019205128A1 (OSRAM)
BR (1) BR112020013244A2 (OSRAM)
CA (1) CA3087135A1 (OSRAM)
IL (1) IL275691A (OSRAM)
MX (1) MX2020006822A (OSRAM)
RU (1) RU2020116541A (OSRAM)
TW (1) TW201932487A (OSRAM)
WO (1) WO2019135159A2 (OSRAM)
ZA (1) ZA202003893B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527496B (zh) * 2020-04-16 2022-03-04 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
EP4135733A4 (en) * 2020-04-17 2024-06-26 University of Cincinnati MODIFIED PROBIOTICS FOR TREATMENT AND IMMUNITY AGAINST VIRUSES
CA3205007A1 (en) * 2020-12-17 2022-06-23 Parasol Biotech Ltd. Gucy2c binding molecules and uses thereof
WO2022152862A1 (en) * 2021-01-14 2022-07-21 Institut Curie Her2 single domain antibodies variants and cars thereof
CN118215685A (zh) * 2021-12-27 2024-06-18 山东先声生物制药有限公司 抗gucy2c抗体及其应用
WO2023198008A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Compositions and methods for treating cancer
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
CN119604536A (zh) * 2022-05-23 2025-03-11 塞雷乌斯股份有限公司 Her2结合剂及其用途
CN116655806B (zh) * 2023-05-31 2024-01-05 四川大学华西医院 包含shp2 c-sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
ES2528922T3 (es) * 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
WO2009068631A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA2757382A1 (en) * 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
GB201010389D0 (en) * 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives

Also Published As

Publication number Publication date
BR112020013244A2 (pt) 2020-12-01
KR20200106032A (ko) 2020-09-10
CA3087135A1 (en) 2019-07-11
MX2020006822A (es) 2020-09-03
WO2019135159A2 (en) 2019-07-11
EP3735420A4 (en) 2021-10-06
EP3735420A2 (en) 2020-11-11
WO2019135159A3 (en) 2020-02-13
CN112272673A (zh) 2021-01-26
JP2023126935A (ja) 2023-09-12
RU2020116541A3 (OSRAM) 2022-02-28
ZA202003893B (en) 2022-11-30
US20220056149A1 (en) 2022-02-24
RU2020116541A (ru) 2022-02-04
US20190202931A1 (en) 2019-07-04
AU2019205128A1 (en) 2020-07-16
IL275691A (en) 2020-08-31
JP2021511013A (ja) 2021-05-06

Similar Documents

Publication Publication Date Title
US20220056149A1 (en) Single-domain antibody-cytosine deaminase fusion proteins
TWI840386B (zh) 抗間皮素抗體
US11466088B2 (en) VEGFR-2 car immune cells to treat cancers
JP2024056795A (ja) Ｃｄ７３に対する抗体分子及びその使用
US12427203B2 (en) Long acting multi-specific molecules and related methods
TW201841661A (zh) 包含類鐸受體(toll-like receptor)促效劑之抗體結合物及組合療法
JP2021524268A (ja) Ｐｄ−ｌ１及びｃｄ１３７に結合する抗体分子
CN111655726A (zh) 抗叶酸受体α抗体偶联物和其用途
CN112601554A (zh) 肿瘤微环境活化的药物-结合剂缀合物和与其相关的用途
CN116322754A (zh) Il10ra结合分子及使用方法
JP2023061976A (ja) Ｖｅｇｆｒ－２抗体
US20240352122A1 (en) Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
CA3253669A1 (en) Anti-CD39 antibodies and their use
US12006356B2 (en) Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
CN116802207A (zh) Il10rb结合分子及使用方法
CN116194481A (zh) 抗-IL13Rα2抗体
KR102957804B1 (ko) Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법
HK40036942A (en) Single-domain antibody-cytosine deaminase fusion proteins
EP3580242A1 (en) Anti-vegfr-2 urease conjugates
TW202508639A (zh) 包含使用活性碳材料之純化步驟的抗體-藥物結合物之製造方法
HK40124330A (zh) 抗cd39抗体及其用途
CN120202022A (zh) 细胞靶向构建体及其用途
HK40035117B (zh) 抗tigit抗体及其用途